BioSyent (CVE:RX) Share Price Crosses Below 200-Day Moving Average – Here’s What Happened

BioSyent Inc. (CVE:RX)’s share price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of C$13.97 and traded as low as C$13.85. BioSyent shares last traded at C$13.95, with a volume of 87,690 shares changing hands.

BioSyent Trading Up 0.6%

The company has a debt-to-equity ratio of 11.66, a quick ratio of 6.91 and a current ratio of 1.89. The firm has a market capitalization of C$158.08 million, a P/E ratio of 17.79 and a beta of 1.02. The firm has a 50-day moving average of C$14.37 and a 200-day moving average of C$13.97.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.